G-33040* a new antidepressant drug, is iminostilbene -N-propane -piperazineethanol. It contains imiprimaine like imi nostilbene nucleus and a side chain with the piperazine group, similar to perphen azine, a tranquillizer. From the chemical formula it can be expected that the com pound will have both antidepressant and tranquillizing effects. It was reported to have antidepressant and activating pro perties similar to but less pronounced than imipramine hydrochloride. Kristof, Macpherson and Brown (1962) reported that G-33040 was a safe antidepressant with an anti-anxiety ef fect, useful in a general hospital setting. It was also reported to produce less frequent and milder side effects than those occuring with imipramine. Conse quently this drug has been recommended for treatment of mild, neurotic depres sion*. The present study reports the re sults of a controlled clinical trial of G-33040 in a group of mildly depressed patients treated in the out-patient depart ment of a general hospital.
Subjects
Patients diagnosed as: mild psychotic depression, depression in involutional setting, neurotic depression, psychoneurosis with depressive features and hypo chondriacal reactions of depressive na ture were included in the study. They were treated as out-patients, were their own controls and apart from the drug received no other therapy. Patients in whose case there was a possibility of early schizophrenia, or of an organic brain damage and also pregnant women were not included in the study***. Orig inally 27 patients were included, how ever 13 failed to keep the appointments and had to be excluded. Fourteen pa tients finished the study. The effects of the drug on these patients as well as in complete data regarding side effects in three additional patients are reported in this paper. The final experimental group included 11 women and three men. The average age of the subjects was 39 years seven months (range 22-52 years). They came from the low social-economic group and were treated in the out-pa tient department as indigents.
Method
This study was 'double blind' with patients acting as their own controls. 'Cross-over' ('switch-back') design was used. The patients were assigned at ran dom to two groups (each group seven patients). Each group had two periods of treatment. One group received the active drug first and placebo second, the other group received placebo first and the active drug second. The placebo had the same appearance as the drug. The drug was given in the dose of 50 mgm. tablets three times a day. The whole clinical trial for each patient lasted 46 days divid ed as follows: 21 days on one compound tttGeigy Pharmaceuticals informed the author that an unconfirmed study on rats showed that G-33040 could produce deformities in fetuses, (personal com munication.)
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(first period), four days on no medica tion, 21 days on the other compound (second period). Each patient was inter viewed and assessed four times: 1) at the beginning of the first 21-day period, 2) at the end of the 21-day period, 3) at the beginning of the second 21day period, and 4) at the end of the second 21-day period.
The patients were rated at the end of each interview on the Hamilton Rating Scale for Depression (1) . This scale con sists of 22 subscales on which various symptoms of depression are rated. In the present study in the analysis of data both total score and the scores obtained on the subscales were used. The score was the difference between the ratings at the beginning and at the end of each treat ment period. Side effects, if present, were recorded. In addition the following laboratory tests were carried out three times (at the beginning of the first 21day period at the end of the first 21-day period and at the end of the second 21day period): 1) red and white blood cell counts, 2) urine bile, 3) urine sugar, 4) serum cephaline, 5) blood cholesterol, 6) serum globuline flocculation test, 7) serum alkaline phosphatase test.
Results
The analysis of variance of the total scores obtained on the Hamilton Rating Scale for Depression showed that the difference between the drug and the placebo was very significant. (Difference between the mean scores: 6.00, F=12.35, d.f.1, p<.01) **.
It was of some interest to establish which particular symptoms of depression were affected by the drug. Consequently, the differences in the score of the two groups (drug-placebo and placebo-drug) on 22 subscales of the Hamilton Rating Scale were tested by a form of 't' test adapted for the 'cross-over design.
It was found that initial insomnia (difficulty in falling asleep), general somatic symptoms, gastro-intestinal symptoms and agitation were significant ly affected by the drug (p < .05). Som atic anxiety depressed mood were af fected to a lesser extent (p < .10) * *.
Side effects: Since evidence regarding side effects was obtained from an addi tional three patients (total of 17 patients as against 14 patients who finished the study) two analyses were carried out. Table 1 presents the number of patients out of the total number of 17 who devel oped various side effects either on the drug or on the placebo. It can be seen that 15 patients devel oped side effects when on the drug as against 14 who developed side effects when on the placebo. One patient dis continued taking the drug and one pa tient discontinued taking placebo be cause of side effects. In addition to this analysis of the side effects another analy sis based on the patient who had com pleted the study was carried out in the following way: severe symptoms were given a weighting of two, mild symp toms were given a weighting of one, the averages were calculated for the two * fl Further information can be obtained on request from the author. groups (drug-placebo and placebo-drug) and the significance of the difference was assessed by the't' test. The difference of the means was +0.6 (means -j-0.6 and 0, t=0.508, 12 d.f., n.s.). The patients on the drug had slightly a higher number of side effects than patients on the placebo. This difference did not even approach the level of significance. The results of all the laboratory tests were negative. It seems that patients developed numerous side ef fects when both on the drug and the placebo. Undoubtedly many of these side effects were due to suggestion caused by questioning and a negative placebo effect. A typical comment of an examining psy chiatrist regarding side effects is the following one: "Not significant -all concomitant (to treatment) complaints are in keeping with patient's neurotic character." Two side effects were prob ably due to the taking of the drug. Two patients developed rashes when on the drug. In the case of one patient the rash was described by the examining psy chiatrist as follows: "Patchy, itchy rash all over her body, worse on arms, legs and chest -four days after starting med ication. Rash cleared up after discon tinuing medication." One patient com plained when on the drug of "dizziness when changing posture.") This could have been .caused by orthostatic hypo tension. Thus the drug could have caused skin rash and dizziness due to postural hypotension.
Discussion
The results of the study show that G-33040 is effective in the treatment of depression. The subjects of this study were rather difficult patients to treat. They came from the low social econ omic class and sometimes were transients. There was very often a great deal of environmental stress caused by poverty, broken home, unhappy marriage and general insecurity. Since the patients re ceived practically no psychotherapy the drug was the only treatment they had.
The following symptoms of depres sion were mainly affected (improved) by G-33040: difficulty in falling asleep, general somatic and particularly gastro intestinal symptoms, agitation and to a lesser extent somatic anxiety and de pressed mood. It appears that G-33040 is effective in cases of depression in an in volutional setting with somatic anxiety and preoccupation, and also in cases of depression in a setting of character neu rosis, e.g. hysterical personality. This impression is confirmed by the great number of side effects, which the patients developed while either on the drug or on the placebo.
A-Iany of these side effects could be due to a negative placebo reaction in hostile patients with hysterical features. The subjects of the study tended to be placebo reactors, both in positive and negative ways. This placebo effect, which possibly manifested itself in a trend for the first period treatment to be more effective than second, was partialed out by the 'cross-over' experimental design.
As far as the side effects specifically caused by the drug are concerned it seems that G-33040 may cause an allergic reaction in the form of a skin rash and also may produce postural hypotension. In conclusion it can be stated that G-33040 is a relatively safe*** drug, useful in the treatment of neurotic and agitated depressives on an out-patient basis.
Probably it is not a drug of choice in cases of psychotic retarded depression.
Summary
Controlled clinical trial of G-33040 was conducted in a group of 14 mildly de pressed out-patients, using the 'cross over' design. The drug was found to be effective in treatment of depression, particularly of the agitated type with somatic preoccupations and also the one in a character neurosis setting. The possible side effects were skin rash and dizziness due to postural hypotension. 
